Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 5, 2008, Pages 905-908

  Lambert Niclot, Sidonie ^a,b   Flandre, Philippe ^c   Malet, Isabelle ^a,b   Canestri, Ana ^b,c   Soulié, Cathia ^a,b   Tubiana, Roland ^b,c   Brunet, Christel ^a,b   Wirden, Marc ^a,b   Katlama, Christine ^b,c   Calvez, Vincent ^a,b   Marcelin, Anne Geneviève ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c INSERM   (France)

Author keywords

Drug resistance; HIV; Protease inhibitors; Risk factors

Indexed keywords

ANTIRETROVIRUS AGENT; DARUNAVIR; GAG PROTEIN; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

AMINO ACID SEQUENCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; GENE MUTATION; GENETIC SELECTION; GENOTYPE; HEREDITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; NONHUMAN; REBOUND; RISK FACTOR; TREATMENT DURATION; VIRUS ISOLATION;

AMINO ACID SEQUENCE; DRUG RESISTANCE, VIRAL; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV PROTEASE; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; SELECTION (GENETICS); SULFONAMIDES;

EID: 54549097140     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn338     Document Type: Article

References (13)

1. Clotet B, Bellos N, Molina JM et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369: 1169-78.
2. Clumeck N, van Lunzen J, Chiliade P et al. ARTEMIS: Efficacy and safety of lopinavir (BID vs QD) and darunavir (QD) in antiretroviral-naive patients. In: Abstracts of the Eleventh European AIDS Conference, Madrid, 2007. Abstract LBPS7/5. http://www.eacs.eu/ conference/madrid07/documents/ABS00033.
3. De Meyer S, Azijn H, Surleraux D et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005; 49: 2314-21.
4. Koh Y, Towata T, Ghosh AK et al. In-vitro selection of HIV-1 variants highly resistant to darunavir (DRV) using a mixture of HIV-1 isolates resistant to multiple protease inhibitors (PIs). In: Abstracts of the Fourteenth Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2007. Poster 606. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
5. De Meyer S, Hill A, De Baere I et al. Effect of baseline susceptibility and on-treatment mutations on TMC114 and control PI efficacy: Preliminary analysis of data from PI-experienced patients from POWER1 and POWER2. In: Abstracts of the Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver, CO, 2006. Abstract 157. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
6. Lambert-Niclot S, Flandre P, Canestri A et al. Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir. Antimicrob Agents Chemother 2008; 52: 491-6.
7. Mammano F, Petit C, Clavel F. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J Virol 1998; 72: 7632-7.
8. Callebaut C, Stray K, Tsai L et al. In vitro HIV-1 resistance selection to GS-8374, a novel phosphonate protease inhibitor: Comparison with lopinavir, atazanavir and darunavir. In: Abstracts of the Sixteenth International HIV Drug Resistance Workshop, Barbados, West Indies, 2007. Antivir Ther 2007; 12: S18.
9. Nijhuis M, van Maarseveen NM, Lastere S et al. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med 2007; 4: E36.
10. Johnson VA, Brun-Vezinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med 2008; 16: 62-8.
11. Parkin N, Chappey C, Lam E et al. Reduced susceptibility to protease inhibitors (PI) in the absence of primary PI resistance-associated mutations. In: Abstracts of the Fourteenth International HIV Drug Resistance Workshop, Quebec City, Canada, 2005. Antivir Ther 2005; 10: S118.
12. De Meyer S, Azijn H, Fransen E et al. The pathway leading to 114 resistance is different for TMC114 compared with other protease inhibitors. In: Abstracts of the Fifteenth International HIV Drug Resistance Workshop, Sitges, Spain, 2006. Antivir Ther 2006; 11 S24.
13. Nijhuis M, Wensing A, Bierman W et al. A novel genetic pathway involving L76V and M46I leading to lopinavir/r resistance. In: Abstracts of the Sixteenth International HIV Drug Resistance Workshop, Barbados, West Indies, 2007. Antivir Ther 2007; 12: S140.